Did you mean heat rice construct in sb lal c chickens?
Displaying drugs 11601 - 11625 of 11739 in total
MK-1064
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics …
PD-0299685
PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).
Investigational
Matched Description: … PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the …
Nisoxetine
Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. It has been used to research obesity and energy balance, and exerts some local analgesia effects.
Experimental
Matched Description: … Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. …
Dasotraline
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
Investigational
MK-1454
A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB)...
Investigational
Matched Description: … This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. ... immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines ... TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in …
GC-373
GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription . GC-373 has been shown to inhibit the Mpro...
Experimental
Matched Description: … 3CLpro), a viral encoded protease that cleaves and activates functional proteins involved in ... GC-373 has been shown to inhibit the Mpro target in various coronavirus strains, including ... Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov …
ZYCOV-D
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … As of August, 2020 the candidate is in Phase II clinical trials[A219758]. ... The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758]. ... Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting …
αAβ–Gas6
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic ... binding domain of growth arrest-specific 6 (Gas6), which is a ligand for receptor kinases expressed in ... αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the amyloid plaques found in …
Tilmicosin
Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.
Investigational
Vet approved
Matched Description: … It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory …
Tabalumab
Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
Investigational
Matched Description: … Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, …
Presatovir
Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Infections, and Respiratory Syncytial Virus (RSV) Infections.
Investigational
Matched Description: … Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus …
Iboctadekin
Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Investigational
Matched Description: … Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to …
Girentuximab I-124
Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).
Investigational
Matched Description: … Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal …
Neihulizumab
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
Investigational
Matched Description: … checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in …
Efzofitimod
Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Investigational
Matched Description: … is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in …
Talopram
Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.
Experimental
Matched Description: … It was researched in the 1960s and 1970s but never marketed. …
Emibetuzumab
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Investigational
Matched Description: … Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, …
Lumretuzumab
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Investigational
Matched Description: … Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small …
Milatuzumab
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), …
Rovalpituzumab tesirine
Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Investigational
Matched Description: … Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma …
Demegestone
Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.
Experimental
Matched Description: … It was previously marketed in France as Lutionex, but has since been discontinued. …
TZP-102
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
Matched Description: … TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration …
Paltusotine
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety …
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Description: … It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] …
Displaying drugs 11601 - 11625 of 11739 in total